NeuroBo Pharmaceuticals is a clinical-stage biotechnology company. Co.'s therapeutics programs include: ANA001, its drug candidate developed as a treatment for patients with moderate coronavirus disease (COVID-19); NB-01, which is focused on the development of a treatment for diabetic neuropathy, including chemotherapy-induced peripheral neuropathy and post-traumatic peripheral neuropathy; NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases related with the malfunction of a protein called tau, and with amyloid beta plaque deposition; and Gemcabene, which is being assessed as an acute indication for COVID-19. The NRBO stock yearly return is shown above.
The yearly return on the NRBO stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the NRBO annual return calculation with any dividends reinvested as applicable (on ex-dates).
|